Foqus Technologies’ DeepFoqus-Accelerate Receives FDA Clearance

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Foqus Technologies recently announced that their AI-powered MRI reconstruction software, DeepFoqus-Accelerate, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Powered by Foqus's proprietary AI technology, DeepFoqus integrates with existing MRI systems and workflows to reduce scan times by 75% while maintaining image quality comparable to standard non-accelerated scans. This FDA clearance marks a key milestone in Foqus' journey to bring DeepFoqus to the market.

Foqus Technologies is an OBIO® member, an alumnus of our CAAP® program, part of our Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Novartis Canada Extends Health Equity Initiative
Next

Cosm Medical Secures First Tranche of Seed Extension